

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addiese: COMMISSIONER FOR PATENTS PO Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|--|-------------|----------------------|---------------------|------------------|
| 10/812,839 | 03/30/2004 | Lalit M. Bharadwaj | U 015121-7 | 3629 |
| 140 7590 02/22/2008 LADAS & PARRY LLP | | EXAMINER | | |
| 26 WEST 61ST STREET | | | LIN, JERRY | |
| NEW YORK, | NY 10023 | | ART UNIT | PAPER NUMBER |
| | | | 1631 | |
| | | | | |
| | | | MAIL DATE | DELIVERY MODE |
| | | | 02/22/2008 | PAPER |

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

| Application No. | Applicant(s) | |
|-----------------|------------------------|---|
| 10/812,839 | BHARADWAJ ET AL. | |
| Examiner | Art Unit | |
| JERRY LIN | 1631 | |
| | 10/812,839 Examiner | 10/812,839 BHARADWAJ ET A Examiner Art Unit |

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address -THE REPLY FILED 28 January 2008 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, application, application, application and timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:

a) The period for reply expires 3 months from the mailing date of the final rejection.

b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.

Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filled is the date for purposes of determining the period of evaluation and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filled, may reduce any earned patent term adjustment. See 37 CFR 1.79(a).

NOTICE OF APPEAL

2. The Notice of Appeal was filed on _____ A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).

AMENDMENTS

- 3. ☐ The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because

 (a) ☐ They raise new issues that would require further consideration and/or search (see NOTE below);

 (b) ☐ They raise the issue of new matter (see NOTE below);

 (c) ☐ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for
 - appeal; and/or
- (d) They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: ______ (See 37 CFR 1.116 and 41.33(a)).
- 4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).
- Applicant's reply has overcome the following rejection(s):

 Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).
- 7. For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: _____.

Claim(s) objected to: _____.
Claim(s) rejected: 1.2.4.5.11.13.17 and 22-32.

Claim(s) withdrawn from consideration: 19.

AFFIDAVIT OR OTHER EVIDENCE

- 8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 OFR 1.116(e).
- 9. In the affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will <u>not</u> be entered because the affidavit or other evidence failed to overcome <u>all</u> rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).
- 10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

REQUEST FOR RECONSIDERATION/OTHER

- 11. \(\bigcirc \) The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See note.
- 12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s).

13. Other: .

/Marjorie A. Moran/ SPE, AU 1631 2/18/08 Continuation of Notes 7 and 11:

Rejection made under 35 U.S.C §112 2nd Paragraph.

Applicants have amended claims 1 and 22 to clarify that storage DNA consists of a mixture of homogenous/heterogeneous DNA. This rejection is withdrawn.

Rejection made under 35 U.S.C. \$103 as being unpatenable over Bancroft et al. in view of Ackley.

The Applicants first state that Bancroft et al. does not teach the encrytion of the the standard 256 ASCII characters. The Examiner agrees, but maintains that is it obvious to do so in view of Ackley.

The Applicants also state that the Bancroft et al. method cannot represent digital documents like images/ audio/ video, etc. However digital documents are not a limitation in the claims and cannot be used to distinguish the instant claims from the prior art.

The Applicants state that Ackley does not teach using the four unique bases to represent the 256 ASCII characters. The Examiner agrees, however, the Examiner relies on the combination of Bancroft et al. and Ackley to make obvious using the 4 unique DNA bases to represent 256 ASCII character. In this case, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); In re Merck & Co., 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1980).

The Applicants state that Ackiey does not provide a motivation to use a character set comprising DNA bases. However, KSR International Co. v. Teleflex Inc. forecloses the argument that a specific teaching, suggestion, or motivation is required to support a finding of obviousness. See the recent Board decision Ex parts Smith (Bd. Pat. App. & Interf. June 25, 2007). In the instant case, the claims would have been obvious because the technique for improving the codes to include more characters was part of the dimary capabilities of a person of ordinary skill in the art, in view of the teaching of the technique for improvement in other situations. Both Ackley and Bancroft et at leach ways to improve the method of enocing messages. Ackley teaches a well known method of increasing the length of the code (columns 1 and 2). Thus, it would have been precidable to one of ordinary skill in the art that increasing the length of the code by Bancroft et al. would also increase the capacity of Bancroft et al.'s code to encode more characters. One of ordinary skill in the art would reasonably expect that adding one more base codes to Bancroft et al.'s method would allow one to encode the entire 256 ASCII character set.

Applicants particularly point out claim 22 and state that Bancroft et al. do not teach that a plurality of molecules each encoding different portions of the same message. The Examiner disagrees. Bancroft et al. teach (column 6, lines 30-42) that periunity of messages may be encoded in the plurality of DNA molecules. However, all of these messages may be intended for the same recipient (column 3, lines 19-33). Thus each molecule encodes a different portion of the same message. Bancroft et al. do teach the instant claims.

Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to JERRY LIN whose telephone number is (371)272-2861. The examiner can normally be reached on 10:00-6:30, M-F. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marjorie A. Moran can be reached on (571)

272-0720. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patient Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or bulbie PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspho.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 627-79-197 (biffee). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/JL/